-
公开(公告)号：US20140187756A1
公开(公告)日：2014-07-03
申请号：US14181649
申请日：2014-02-15
Applicant: LegoChem Biosciences, Inc.
Inventor： Yongzu Kim , Taekyo Park , Sungho Woo , Hyangsook Lee , Sunyoung Kim , Jongun Cho , Doohwan Jung , Youngun Kim , Hyunjin Kwon , Kyuman Oh , Yunseo Chung , Yun-Hee Park
CPC classification number: A61K47/6811 , A61K47/549 , A61K47/55 , A61K47/65 , A61K47/6803 , A61K47/6817 , A61K47/6849 , A61K47/6851 , A61K47/6855 , A61K47/6859 , A61K47/6889 , C07K16/2863 , C07K16/32 , C12Q1/48
Abstract: The invention provides methods for preparing an antibody-active agent conjugate. The conjugate comprises an antibody, a cysteine residue of an amino acid motif that can be recognized by an isoprenoid transferase located at or after the carboxy-terminus of the antibody, an isoprenoid unit operably linked to the cysteine residue, and an active agent. The invention also provides a composition comprising the antibody-active agent conjugate prepared by the methods.
Abstract translation: 本发明提供了制备抗体 - 活性剂缀合物的方法。 缀合物包含抗体，氨基酸基序的半胱氨酸残基，其可被位于抗体的羧基末端或之后的类异戊二烯转移酶识别，与半胱氨酸残基可操作地连接的类异戊二烯单元和活性剂。 本发明还提供包含通过该方法制备的抗体 - 活性剂缀合物的组合物。
-
公开(公告)号：US11707533B2
公开(公告)日：2023-07-25
申请号：US16940326
申请日：2020-07-27
Applicant: LegoChem Biosciences, Inc. , ABL Bio, Inc.
Inventor： Yun-Hee Park , Ho Young Song , Hyun Min Ryu , Sung Min Kim , Ju Yuel Baek , Ji Hye Oh , Nara Han , Hyoung Rae Kim , Kyung Eun Park , Hyeun Joung Lee , Ju Young Lee , Dae Hyuck Kang , Young-Jae Yang , Ji-Na You , Yong Zu Kim , Chang Sun Lee , Jeiwook Chae , Jinwon Jung , Juhee Kim , Bora Lee , Daehae Song , Byungje Sung , Donghoon Yeom , Jaehyun Eom , Youngeun Hong , Jinhyung Ahn , Yangsoon Lee , Kyungjin Park , Jiseon Yoo , Minji Park
CPC classification number: A61K47/6849 , A61K47/6803 , A61P35/00 , C07K16/2803
Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
-
公开(公告)号：US20220096641A1
公开(公告)日：2022-03-31
申请号：US17420007
申请日：2020-01-03
Applicant: LEGOCHEM BIOSCIENCES, INC.
Inventor： Ho Young SONG , Juyuel BAEK , Sung Min KIM , Hyoung Rae KIM , Hyeun Joung LEE , Ju Young LEE , Kun Jung LEE , Yun-Hee PARK , Chang Sik PARK , Hwan Hee OH , Jihye OH , Jeiwook CHAE , Yong Zu KIM , Sang Eun CHAE , Hyunmin RYU , Nara HAN , Min Ji CHOI
IPC: A61K47/55 , A61K47/68 , A61P35/00 , C07D487/04 , C07H15/26
Abstract: The present invention relates to a novel pyrrolobenzodiazepine dimer compound or a pharmaceutically acceptable salt thereof, a ligand-drug conjugate compound thereof, or a composition containing the same and therapeutic use of the same as an anticancer agent. The pyrrolobenzodiazepine dimer compound according to the present invention exhibits anticancer activity equivalent to or superior to that of existing anticancer agents when being applied to a ligand-drug conjugate as a drug and administered as well as exhibits low activity and greatly diminished toxicity in the free toxin form and thus has a significantly improved therapeutic index. Hence, the pyrrolobenzodiazepine dimer compound is highly industrially applicable in that targeting of proliferative diseases such as cancer is possible, specific treatment of the proliferative diseases is possible, the drug efficacy can be maximized, and the expression of side effects can be minimized.
-
公开(公告)号：US11173214B2
公开(公告)日：2021-11-16
申请号：US15779444
申请日：2016-11-23
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Yun Hee Park , Hyo Jung Choi , Kyung Eun Park , Hyoungrae Kim , Jinyeong Kim , Ji Young Min , Sung Min Kim , Byung Soo Lee , Dong Hyun Woo , Ji Eun Jung , Su In Lee
Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody.
-
公开(公告)号：US10980890B2
公开(公告)日：2021-04-20
申请号：US16545869
申请日：2019-08-20
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Tae Kyo Park , Sung Ho Woo , Sun Young Kim , Jong Un Cho , Doo Hwan Jung , Ji Young Min , Hyang Sook Lee , Yun Hee Park , Jeong Hee Ryu , Kyu Man Oh , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Jeon Yang
IPC: A61K47/54 , C07K19/00 , C07D487/04 , C07D519/00 , A61K47/68 , A61K47/50 , C07D249/04 , C07K16/32 , A61K47/69 , A61K39/00
Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
-
Patent Agency Ranking
公开(公告)号：US10961242B2
公开(公告)日：2021-03-30
申请号：US16783893
申请日：2020-02-06
Applicant: LegoChem Biosciences, Inc.
Inventor： Dae Yon Lee , Sang Eun Chae , Eun Mi Jung , Eun Hye Yang , Yoon Jeong Choi , Chul-Woong Chung , Ju Hyun Shin , Yun Ki Kim , Hyun Jin Kwon , Jeong Hee Ryu , Eun Hye Ban , Yong Zu Kim , Yeong Soo Oh , Jeiwook Chae
IPC: C07D471/04 , C07D498/10 , C07D519/00 , C07D471/10 , C07D413/14 , C07D413/12 , C07D403/14 , C07D401/14 , C07D513/04
Abstract: The present invention relates to novel compounds as autotoxin inhibitors for treatment and prophylaxis of conditions or a disorder caused by autotaxin activation or increased concentration of lysophosphatidic acid, and also a pharmaceutical composition containing the same.
The novel compounds of the present invention are autotoxin inhibitors, and by inhibiting the production of lysophosphatidic acid, they are useful for treatment or prophylaxis of cardiovascular disorder, cancer, metabolic disorder, kidney disorder, liver disorder, inflammatory disorder, nervous system disorder, respiratory system disorder, fibrotic disease, ocular disorder, cholestatic and other forms of chronic pruritus, or acute or chronic organ transplant rejection.-
公开(公告)号：US20200069816A1
公开(公告)日：2020-03-05
申请号：US16545869
申请日：2019-08-20
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Tae Kyo Park , Sung Ho Woo , Sun Young Kim , Jong Un Cho , Doo Hwan Jung , Ji Young Min , Hyang Sook Lee , Yun Hee Park , Jeong Hee Ryu , Kyu Man Oh , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Jeon Yang
IPC: A61K47/68 , A61K47/69 , C07K16/32 , C07D249/04 , A61K47/54 , C07D519/00 , C07D487/04 , C07K19/00 , A61K47/50
Abstract: Provided herein are compounds comprising a self-immolative group, and the compounds comprising a self-immolative group according to the present invention may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
-
公开(公告)号：US10273235B2
公开(公告)日：2019-04-30
申请号：US15917059
申请日：2018-03-09
Applicant: LegoChem Biosciences, Inc.
Inventor： Hye Kyung Chang , Sung Yoon Baek , Min Jung Kim , Kyu Man Oh , Jeung Soon Choi , Soo Bong Ha , Sung Min Kim , Chul-woong Chung , Dae Hyuck Kang , Hyun Jin Kwon , Young Lag Cho , Yong Zu Kim
IPC: A61K31/46 , C07D471/08 , C07D519/00
Abstract: Substituted dihydroisoxazole derivatives useful as inhibitors of β-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.
-
公开(公告)号：US09993568B2
公开(公告)日：2018-06-12
申请号：US14898932
申请日：2015-05-27
Applicant: LegoChem Biosciences, Inc.
Inventor： Yong Zu Kim , Tae Kyo Park , Sung Ho Woo , Sun Young Kim , Jong Un Cho , Doo Hwan Jung , Ji Young Min , Hyang Sook Lee , Yun Hee Park , Jeong Hee Ryu , Kyu Man Oh , Yeong Soo Oh , Jeiwook Chae , Ho Young Song , Chul-Woong Chung , Jeon Yang
CPC classification number: A61K47/6871 , A61K47/549 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6813 , A61K47/6855 , A61K47/6889 , A61K47/69 , A61K2039/505 , C07D249/04 , C07D487/04 , C07D519/00 , C07K16/32 , C07K19/00 , C07K2317/24
Abstract: Provided are methods of use of compounds comprising a self-immolative group, which compounds may include a protein (for example, an oligopeptide, a polypeptide, an antibody, or the like) having substrate-specificity for a target and an active agent (for example, a drug, a toxin, a ligand, a detection probe, or the like) having a specific function or activity.
-
公开(公告)号：US09630977B2
公开(公告)日：2017-04-25
申请号：US13691221
申请日：2012-11-30
Applicant: Legochem Biosciences, Inc.
Inventor： Young Lag Cho , Joung Yul Yun , Sang Eun Chae , Chul Soon Park , Hyang Sook Lee , Kyu Man Oh , Hye Jin Heo , Dae Hyuck Kang , Young Jae Yang , Hyun Jin Kwon , Tae Kyo Park , Sung Ho Woo , Yong Zu Kim
IPC: C07D501/24 , C07D501/46 , C07D501/60
CPC classification number: C07D501/60 , C07D501/24 , C07D501/46
Abstract: The present invention relates to novel cephalosporin derivatives represented by X, Y, L, R1, and R2 are as same as defined in the description of the invention. The present invention also relates to pharmaceutical antibiotic compositions comprising a novel celphalosporin derivative represented by Chemical Formula 1, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient. According to the present invention, novel cephalosporin derivatives, a prodrug thereof, a hydrate thereof, a solvate thereof, an isomer thereof, or a pharmaceutically acceptable salt thereof as an effective ingredient for the broad spectrum of antibiotic resistant, low toxicity, particularly in Gram-negative bacteria, which can be useful with strong antimicrobial activity.
-
-
-
-
-
-
-
-
-
Search Results
51
records
(took 0.042 seconds)
